Trials / Completed
CompletedNCT00922701
L-Carnitine in Peritoneal Dialysis
Phase 2 Study of Dialysis Efficiency and Tolerability of Nocturnal Peritoneal Dialysis Solution Containing Glucose Plus L-carnitine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Iperboreal Pharma Srl · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy. The study hypothesis is to evaluate the possibility to formulate peritoneal dialysis solutions containing L-carnitine as an osmotic agent to partially replace glucose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | L-carnitine | Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days. |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2004-10-01
- Completion
- 2004-12-01
- First posted
- 2009-06-17
- Last updated
- 2010-02-23
- Results posted
- 2009-06-17
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00922701. Inclusion in this directory is not an endorsement.